Project Grant R43HL182585
Award Date 9/15/25
Completion Date 9/14/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $395,306 Project Grant to Cutcath LLC under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant aims to examine the safety and efficacy of Cutcath's novel Dissection Septum Cutting Catheter (DSCC) device, which is designed to facilitate endovascular treatment of acute aortic dissections. The DSCC uses radiofrequency and a specialized catheter design to completely fenestrate the aortic dissection...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...
- This Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a unique antimicrobial vascular catheter to prevent catheter-related bloodstream infections (CRBSI). The $272,702 award, effective September 1, 2023, with a completion date of February 29, 2024, will support research and development efforts to create an intravascular catheter with inherent long-lasting antiseptic properties. The...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Peca Labs Inc. to develop a novel, fully-polymeric, biomimetic prosthetic mitral valve. The objective is to create a valve that combines the positive characteristics of both biological and mechanical mitral valves to improve durability, performance, and patient outcomes. Peca Labs will subject the polymer leaflet material to hydrodynamic...